SERPING1 and hereditary angioedema: As shown in Additional file 7: Figure S1, lanadelumab appears to be effective in reducing the rate of HAE attacks in patients in the analyzed population who were (n = 24) and who were not (n = 45) receiving ongoing C1-INH therapy at ATU entry.